Average Insider

Where insiders trade, we follow

$FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Healthcare
Sector
Biotechnology
Industry
Jeffrey S. Hackman
CEO
32
Employees
$10.70
Current Price
$241.89M
Market Cap
52W Low$5.65
Current$10.7089.2% above low, 10.8% below high
52W High$11.31

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells11$99,925.599,599
2 weeksBuys00--All Sells
Sells11$99,925.599,599
1 monthBuys00--All Sells
Sells11$99,925.599,599
2 monthsBuys00--All Sells
Sells23$252,447.5727,692
3 monthsBuys00--All Sells
Sells24$322,200.6438,473
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 1, 2026
Raykov Rosty
Former Director
Sale9,599$10.41$99,925.59View Details
Jun 1, 2026
Raykov Rosty
Director
Sale9,747$9.62$93,766.14View Details
May 11, 2026
RALLIS CHRIS A
Director
Sale8,346$7.04$58,755.84View Details
May 1, 2026
Raykov Rosty
Director
Sale10,781$6.47$69,753.07View Details
18 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
May 11, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
7 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.5.2